Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

XOMA Royalty’s CEO Owen Hughes and CIO Brad Sitko explain how royalty investing mitigates risks while expediting biotech drug development.

AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and sufficiency of disclosure, explains patent attorney Noah K. Tilton.

A looming patent cliff is driving Big Pharma reorganization. Executives making career moves must understand differences in ...

Rick Modi’s background in pharmacy gave him the scientific and analytical chops to pursue an MBA and ultimately lead innovative gene therapy companies.

CEO Rick Modi discusses Affinia’s pipeline, strategic partnerships, and the current gene therapy landscape.

Optimize your clinical trials with Citeline’s Strategic Solutions. Drug development is a lengthy and costly endeavor, often taking 10–15 years and up to $2 billion to bring a therapy to market. To ...

As 2024 concludes, molecular medicine continues its steady 6-7% annual growth, while diversifying its therapeutic landscape. Notably, Q4 brought approvals across gene, cell, and RNA therapies: ...

The North Carolina Biotechnology Center leads life sciences economic development for North Carolina by supporting the progression of ideas from research lab to the marketplace. NCBiotech invests in ...

Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market ...